Emerging concepts on drug resistance in bladder cancer: Implications for future strategies.

[1]  Jin Huang,et al.  Upregulation of Autophagy-Related Gene-5 (ATG-5) Is Associated with Chemoresistance in Human Gastric Cancer , 2014, PloS one.

[2]  G. Packham,et al.  The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer. , 2014, Urologic oncology.

[3]  O. Demirhan,et al.  Genetic alterations of chromosomes, p53 and p16 genes in low- and high-grade bladder cancer , 2014, Oncology letters.

[4]  O. Lee,et al.  S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Dafydd G. Thomas,et al.  Expression of ribonucleoside reductase subunit M1, but not excision repair cross-complementation group 1, is predictive in muscle-invasive bladder cancer treated with chemotherapy and radiation. , 2014, Molecular and clinical oncology.

[6]  Ju-Han Lee,et al.  Expression of β-tubulin isotypes in urothelial carcinoma of the bladder , 2014, World Journal of Urology.

[7]  J. Stenvang,et al.  Measuring ERCC1 protein expression in cancer specimens: Validation of a novel antibody , 2014, Scientific Reports.

[8]  David C. Smith,et al.  Double‐blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma , 2014, Cancer.

[9]  S. Howell,et al.  Copper transporter 2 regulates intracellular copper and sensitivity to cisplatin. , 2014, Metallomics : integrated biometal science.

[10]  A. Hartmann,et al.  Reduced Expression of miRNA-27a Modulates Cisplatin Resistance in Bladder Cancer by Targeting the Cystine/Glutamate Exchanger SLC7A11 , 2014, Clinical Cancer Research.

[11]  K. Baggerly,et al.  Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. , 2014, Cancer cell.

[12]  P. Olbert,et al.  Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells , 2013, BMC Cancer.

[13]  Chawnshang Chang,et al.  Epidermal growth factor enhances androgen receptor‑mediated bladder cancer progression and invasion via potentiation of AR transactivation. , 2013, Oncology reports.

[14]  G. Pond,et al.  Impact of response to prior chemotherapy in patients with advanced urothelial carcinoma receiving second-line therapy: implications for trial design. , 2013, Clinical genitourinary cancer.

[15]  M. Millward,et al.  A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. , 2013, Clinical genitourinary cancer.

[16]  B. Teh,et al.  Molecular targets on the horizon for kidney and urothelial cancer , 2013, Nature Reviews Clinical Oncology.

[17]  G. Kroemer,et al.  ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform , 2013, Cell cycle.

[18]  T. Schuster,et al.  Utility of ATP7B in prediction of response to platinum-based chemotherapy in urothelial bladder cancer. , 2013, Anticancer research.

[19]  G. Santoni,et al.  Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells , 2013, British Journal of Cancer.

[20]  T. Powles,et al.  Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. , 2013, Clinical genitourinary cancer.

[21]  S. Vacher,et al.  microRNA expression profile in a large series of bladder tumors: Identification of a 3‐miRNA signature associated with aggressiveness of muscle‐invasive bladder cancer , 2013, International journal of cancer.

[22]  S. Boorjian,et al.  Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. , 2013, Anticancer research.

[23]  J. Pignon,et al.  ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. , 2013, The New England journal of medicine.

[24]  A. Garazha,et al.  Characteristic patterns of microRNA expression in human bladder cancer , 2013, Front. Gene..

[25]  Peng Guo,et al.  Twist Confers Chemoresistance to Anthracyclines in Bladder Cancer through Upregulating P-Glycoprotein , 2012, Chemotherapy.

[26]  M. Knowles,et al.  A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges , 2012, Advances in urology.

[27]  N. Nonomura,et al.  Co-expression of ERCC1 and Snail is a prognostic but not predictive factor of cisplatin-based neoadjuvant chemotherapy for bladder cancer. , 2012, Oncology letters.

[28]  S. Park,et al.  ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy , 2012, BMC Cancer.

[29]  Jingcheng Dong,et al.  RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: a meta-analysis. , 2012, Lung cancer.

[30]  Daniel Shriner,et al.  Moving toward System Genetics through Multiple Trait Analysis in Genome-Wide Association Studies , 2011, Front. Gene..

[31]  A. Tsujimura,et al.  A Review of ERCC1 Gene in Bladder Cancer: Implications for Carcinogenesis and Resistance to Chemoradiotherapy , 2011, Advances in urology.

[32]  F. Millard,et al.  Update on Chemotherapy in the Treatment of Urothelial Carcinoma , 2011, TheScientificWorldJournal.

[33]  I. Tannock,et al.  A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium , 2011, Investigational New Drugs.

[34]  S. Groshen,et al.  Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  C. Dumontet,et al.  The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer. , 2011, The Lancet. Oncology.

[36]  Yasuo Ohashi,et al.  The prognostic significance of human equilibrative nucleoside transporter 1 expression in patients with metastatic bladder cancer treated with gemcitabine‐cisplatin‐based combination chemotherapy , 2011, BJU international.

[37]  Xiaoping Yang,et al.  Pazopanib synergizes with docetaxel in the treatment of bladder cancer cells. , 2011, Urology.

[38]  R. Fimmers,et al.  Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  N. Nonomura,et al.  Excision Repair Cross-Complementing Group 1 May Predict the Efficacy of Chemoradiation Therapy for Muscle-Invasive Bladder Cancer , 2010, Clinical Cancer Research.

[40]  M. Knowles,et al.  Altered splicing of FGFR1 is associated with high tumor grade and stage and leads to increased sensitivity to FGF1 in bladder cancer. , 2010, The American journal of pathology.

[41]  Bing Xia,et al.  Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination , 2010, Nature Structural &Molecular Biology.

[42]  B. Kaina,et al.  Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression , 2010, Molecular Cancer.

[43]  M. Stöckle,et al.  MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. , 2010, Neoplasia.

[44]  M. Milowsky,et al.  Phase II study of sunitinib in patients with metastatic urothelial cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  C. Dinney,et al.  Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer , 2009, Cancer and Metastasis Reviews.

[46]  G. Wilding,et al.  Phase 2 trial of sorafenib in patients with advanced urothelial cancer , 2009, Cancer.

[47]  Woonyoung Choi,et al.  miR-200 Expression Regulates Epithelial-to-Mesenchymal Transition in Bladder Cancer Cells and Reverses Resistance to Epidermal Growth Factor Receptor Therapy , 2009, Clinical Cancer Research.

[48]  M. Knowles,et al.  Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. , 2009, Cancer research.

[49]  T. H. van der Kwast,et al.  The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour , 2009, The Journal of pathology.

[50]  T. H. van der Kwast,et al.  Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. , 2008, European urology.

[51]  J. Annereau,et al.  Potential mechanisms of resistance to microtubule inhibitors. , 2008, Seminars in oncology.

[52]  C. Dumontet,et al.  Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? , 2008, The Lancet. Oncology.

[53]  Guido Kroemer,et al.  Autophagy in the Pathogenesis of Disease , 2008, Cell.

[54]  M. Knowles,et al.  FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer , 2007, The Journal of pathology.

[55]  D. Amadori,et al.  Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. , 2007, European urology.

[56]  J. Baselga,et al.  Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[58]  E. Giovannetti,et al.  In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients , 2006, British Journal of Cancer.

[59]  S. Groshen,et al.  Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. , 2006, The Journal of urology.

[60]  S. Ricci,et al.  Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer , 2005 .

[61]  L. Sánchez,et al.  Expression of the nucleoside‐derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors , 2004, International journal of cancer.

[62]  John R. Mackey,et al.  The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma , 2004, Clinical Cancer Research.

[63]  Ryuzo Ueda,et al.  Determinants of sensitivity and resistance to gemcitabine: The roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non‐small cell lung cancer , 2004, Cancer science.

[64]  Ning Li,et al.  Nrf2 Is a Key Transcription Factor That Regulates Antioxidant Defense in Macrophages and Epithelial Cells: Protecting against the Proinflammatory and Oxidizing Effects of Diesel Exhaust Chemicals1 , 2004, The Journal of Immunology.

[65]  F. Zunino,et al.  Cellular pharmacology of cisplatin in relation to the expression of human copper transporter CTR1 in different pairs of cisplatin-sensitive and -resistant cells. , 2004, Biochemical pharmacology.

[66]  M. Nakagawa,et al.  Taxol resistance and its reversal by synthetic isoprenoids in human bladder cancer cell line. , 2003, Aktuelle Urologie.

[67]  I. Herskowitz,et al.  Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[68]  Y. Pommier,et al.  Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. , 2002, Cancer research.

[69]  M. Mutoh,et al.  Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. , 2000, Cancer research.

[70]  C. R. Crawford,et al.  Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. , 1998, Cancer research.

[71]  A. Sancar,et al.  Human DNA Repair Excision Nuclease , 1995, The Journal of Biological Chemistry.

[72]  C. Cordon-Cardo,et al.  Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. , 1995, The Journal of urology.

[73]  D. Bajorin,et al.  Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. , 1995, The Journal of urology.

[74]  S C Chen,et al.  Accumulation of nuclear p53 and tumor progression in bladder cancer. , 1994, The New England journal of medicine.

[75]  S. Groshen,et al.  p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. , 1993, The American journal of pathology.

[76]  P. Lipponen.  Over‐expression of p53 nuclear oncoprotein in transitional‐cell bladder cancer and its prognostic value , 1993, International journal of cancer.

[77]  C. Cordon-Cardo,et al.  Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. , 1993, Journal of the National Cancer Institute.

[78]  W. Rose,et al.  In vivo model development of cisplatin-resistant and -sensitive A2780 human ovarian carcinomas. , 1990, In vivo.

[79]  K. Tozawa,et al.  Gemcitabine and docetaxel, an effective second-line chemotherapy for lung metastasis of urothelial carcinoma , 2013, International Journal of Clinical Oncology.

[80]  K. Rieger-Christ,et al.  MicroRNA Profile to Predict Gemcitabine Resistance in Bladder Carcinoma Cell Lines. , 2013, Genes & cancer.

[81]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[82]  M. Taron,et al.  BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[83]  W. Kassouf,et al.  First- and second-line therapy for metastatic urothelial carcinoma of the bladder. , 2011, Current oncology.

[84]  C. Foster,et al.  Pathology of the Urinary Bladder , 2004 .

[85]  I. Pastan,et al.  Biochemical, cellular, and pharmacological aspects of the multidrug transporter. , 1999, Annual review of pharmacology and toxicology.

[86]  T. Tzai,et al.  Reappraisal of the biological role of epidermal growth factor receptor in transitional cell carcinoma. , 1993, European urology.